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Objective: To assess the efficacy and tolerability of a fixed combination of bimatoprost and 
timolol (BTFC) in a large patient sample in a clinical setting.
Methods: In this multicenter, observational, noncontrolled, open-label study, patients (n = 1862) 
with primary open-angle glaucoma or ocular hypertension were treated with BTFC. Assessments 
were made at baseline, six weeks, and three months.
Results: Prior to starting BTFC, 92.3% of patients were taking other ocular hypotensive 
medications. In the overall group at three months, mean intraocular pressure was reduced from 
baseline (21.7 ± 4.5 mmHg and 21.8 ± 4.9 mmHg for the right and left eye, respectively) to 
16.1 ± 3.0 mmHg for each eye (P , 0.0001). The majority of patients (92%) reported no adverse 
events. The most commonly reported adverse events (in .1% of patients) were eye irritation, and 
ocular and conjunctival hyperemia. Adherence to treatment was generally better than (35.4%) 
or the same as (57.5%) with prior therapy. BTFC tolerability was rated as excellent or good by 
92.3% of physicians and 85.8% of patients.
Conclusions: In a large group of patients with primary open-angle glaucoma or ocular 
hypertension, treatment with BTFC was associated with consistent reductions in IOP, improved 
adherence to treatment, and good tolerability.
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Introduction
Glaucoma is the second most common cause of blindness in adults, both in Central 
Europe and worldwide.1 A significant risk factor associated with glaucoma is elevated 
intraocular pressure (IOP).2,3 The importance of IOP as a modifiable risk factor for 
visual field progression in glaucoma is well established.4–8 For example, in the Canadian 
Glaucoma Study, mean IOP at follow-up was significantly associated with visual field 
progression, with every 1 mmHg increment in IOP increasing the risk of progression 
by 19%.4 Other risk factors for glaucoma include increased age, optic disc and visual 
defects, corneal thickness, and myopia.2,3
Commonly prescribed glaucoma medicines may take the form of monotherapies, 
adjunctive combinations, or fixed combination treatments. In the long term, mono-
therapy provides insufficient IOP lowering in the majority of patients.9 However, the 
adjunctive use of several hypotensive medications also has potential disadvantages, 
such as an increased dosing frequency, which has been linked with poor compliance,9–11 Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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the washout effect of multiple instillations,10 and the increased 
adverse event burden of multiple medications.12
Randomized clinical trials have shown that the fixed 
combination of bimatoprost and timolol (BTFC) is effective 
in reducing IOP.13,14 Bimatoprost is a prostamide which is 
thought to lower IOP largely by increasing uveoscleral out-
flow, whereas timolol blocks β-adrenergic receptors in the 
ciliary body, thus decreasing aqueous humor production.15 
In a study comparing BTFC with its individual constituents 
in patients with glaucoma or ocular hypertension, BTFC 
caused a greater reduction in IOP than timolol or bimatoprost 
alone.13 The purpose of this observational study was to assess 
the IOP-lowering efficacy, tolerability, compliance, and 
therapeutic safety of BTFC in a large patient sample in a 
routine clinical setting.
Methods
study design
This was a multicenter, observational, open-label, exploratory, 
noninterventional, nonblinded study conducted in 400 centers 
in Germany. The centers and physicians were selected by 
Allergan GmbH, Germany. Patients were followed over three 
visits, ie, a baseline visit and follow-up visits at six weeks and 
three months. Patients were treated with BTFC (Ganfort®; 
Allergan Inc., Dublin, Ireland; 0.3 mg/mL bimatoprost, 
5 mg/mL timolol) at a dose determined by their physician and 
guided by the summary of product characteristics within the 
clinical setting. Participation in the study did not influence the 
prescription of BTFC or any other drug. Data were gathered 
anonymously, in accordance with German law.
Patients
The study included patients with primary open-angle glau-
coma or ocular hypertension, primarily those with insufficient 
IOP adjustment from previous β-blocker monotherapy.
Measurements
At the first visit, demographic and risk factor information (ele-
vated IOP, family history of glaucoma, visual and optic disc 
defects), previous therapy, and IOP readings were recorded. 
The presence of optic cup and visual field defects was rated on 
a three-step scale (mild, moderate, and advanced). The reasons 
for changing therapy in patients who were receiving previous 
IOP-lowering therapy prior to BTFC treatment were recorded 
according to several categories, ie, insufficient IOP adjust-
ment, appearance of glaucoma-related damage, progression 
of glaucoma-related damage, insufficient tolerability, lack of 
compliance, and other reasons. More than one reason could 
be recorded for each patient. Individual target IOP for right 
and left eyes was recorded.
The primary efficacy variable was the mean change in 
IOP from baseline to end of study at the third visit. IOP 
measurements were made for each eye three times (baseline, 
six weeks, three months) over the study period after switching 
to BTFC.
Other efficacy measures included physician-reported 
assessment of BTFC in terms of IOP reduction using a four-
point scale, ie, excellent, good, moderate, and insufficient. 
Tolerability was assessed by questionnaires completed by 
both physicians and patients at the final examination using 
a four-point scale, ie, excellent, good, moderate, and bad. 
Patient compliance with BTFC was compared with previous 
therapy and rated by the physician as better, equal, or worse. 
All adverse events were recorded at the final visit as free-text 
entries using a questionnaire.
statistical analysis
The planned sample size was 2000 patients from up to 400 
ophthalmology centers; this patient number allowed for the 
detection of uncommon adverse events with an incidence 
of ,0.1% at least once (α = 0.05, binomial distribution). 
Analyses were performed on the total sample unless 
otherwise stated. IOP was calculated as mean and standard 
deviation (SD). A two-sided paired-difference t-test was 
performed on the null hypothesis that IOP does not change 
after three months of study treatment. All statistics were 
performed using SAS® software (version 9.1.3; SAS Institute 
Inc., Cary, NC).
Results
The study included 1862 patients (57.4% female, 42.6% male) 
with primary open-angle glaucoma or ocular hypertension 
(Table 1). Most (72.5%) patients were .60 years old. 
Elevated IOP was the most commonly reported risk factor 
for glaucoma (81%), with 10% reporting both high IOP 
and a family history. The mean time since first diagnosis of 
elevated IOP was 7.7 years. Most patients had at least mild 
visual defects and optic disc defects at the baseline visit. The 
mean target IOP (mean of all individually identified target 
IOP ± SD) for the population was 16.2 ± 2.3 mmHg in both 
the right and left eyes.
Prior therapy
Prior to switching to BTFC, 92.3% of patients (n = 1719) 
were recorded as taking other medications (Table 2). The 
remaining 143 (7.7%) patients either had not been receiving Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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prior IOP-lowering therapy or had no available information 
regarding previous therapy. Prior therapy was timolol-based 
in the majority of patients (57.5%, either monotherapy or in 
combination with other therapies). Three patients (0.2%) 
had previously been using bimatoprost and timolol as an 
adjunctive combination. Of the 1719 patients previously 
taking other medications, 1387 (81%) were taking mono-
therapies, 292 (17%) were taking two adjunctive therapies, 
and 40 (2%) were taking three or more adjunctive therapies. 
Reasons for the change in medication were insufficient IOP 
lowering (86.3%), progression of glaucoma-related damage 
(25.6%), insufficient tolerability (13.1%), lack of compliance 
(11.8%), appearance of glaucoma-related damage (10.4%), 
and other reasons (2.3%), with some patients changing for 
more than one reason.
BTFC therapy
At each visit, the dosage of BTFC was reassessed and 
prescribed as either none, once, twice or more times a day for 
each eye. The most common dose, used by 93.8% of patients, 
was once a day for each eye, as would be expected, given 
that this agent is licensed for once-daily dosing.
At the baseline visit, 88.5% of patients were using BTFC 
alone, 10.3% were using BTFC with additional medication, 
and data were unavailable for 1.2%. At the second visit (mean 
duration of BTFC treatment 6.7 ± 5.3 weeks), 84.6% of 
patients were using BTFC as single therapy, 12.0% were using 
BTFC with additional medication, and data were missing for 
3.4%. At the final visit (mean duration of BTFC treatment 
16.4 ± 8.1 weeks), 80.2% of patients were using BTFC as 
single therapy, 13.4% were taking additional medication, and 
data were unavailable for 6.3%.
effect on iOP
Baseline IOP (mean ± SD) in the total group was 
21.7 ± 4.5 mmHg (n = 1850) and 21.8 ± 4.9 mmHg 
(n = 1853) for the right and left eyes, respectively 
(Figure 1). In the total group at six weeks, mean IOP was 
reduced to 16.6 ± 3.3 mmHg for both right and left eyes 
(Figure 1). At three months, mean IOP was further reduced 
to 16.1 ± 3.0 mmHg for both right and left eyes (Figure 1, 
P , 0.0001 by t-test).
Mean IOP was also calculated for patients with complete 
data (n = 1775 patients with right eye data, n = 1778 patients 
with left eye data). Mean baseline IOP was 21.8 ± 4.5 mmHg 
in the right eye and 21.8 ± 4.8 mmHg in the left eye. After three 
months, mean IOP was 16.1 ± 3.0 mmHg in both the right and 
left eyes for this subset of patients with complete data.
Table 1 Patient demographics at baseline (n = 1862)
Mean ± SD 
(range)
n %
Age (years) 67.1 ± 11.8 
(6–95)
1811
Male 793 42.6
Female 1069 57.4
Elevated IOP first diagnosed 
previous to trial (years)
7.7 ± 6.2 
(1–71)
1300
Corneal thickness (μm)
  right eye 550.5 ± 69.8 
(400–1600)
601
  Left eye 552.4 ± 76.1 
(400–1730)
603
Risk factors
  high iOP 1509 81.0
  Family history of glaucoma 312 16.8
Visual field defects 
  Mild 1454* 57.0
  Moderate 718* 28.0
  Advanced 381* 15.0
  Missing information 1171* n/a
Optic disc defects
  Mild 1235* 45.0
  Moderate 920* 34.0
  Advanced 566* 21.0
  Missing information 1003* n/a
Note: *refers to number of eyes; n = 3724 eyes. 
Abbreviations: iOP, intraocular pressure; n/a, not available; sD, standard deviation.
Table 2 Prior medications taken by .1% of patients, among 
those whose prior therapy was documented (n = 1719)*
Medication n % Active agent(s)
Xalatan® 286 16.6 Latanoprost (0.005%)
Tim®-Ophtal® 195 11.3 Timolol (0.1%, 0.25%, 0.5%)
Timolol 185 10.8 Timolol (0.1%, 0.25%, 0.5%)
Cosopt® 175 10.2 Timolol (0.5%), dorzolamide (0.2%)
Lumigan® 146 8.5 Bimatoprost (0.03%)
Azopt® 144 8.4 Brinzolamide (1%)
Travatan® 135 7.9 Travoprost (0.004%)
Xalacom® 125 7.3 Timolol (0.5%), latanoprost (0.005%)
Trusopt® 74 4.3 Dorzolamide (2%)
Alphagan® 71 4.1 Brimonidine (0.1%, 0.15%) 
DuoTrav® 70 4.1 Timolol (0.5%), travoprost (0.004%)
Betamann® 59 3.4 Metipranolol (0.1%, 0.3%, 0.6%)
Timomann® 54 3.1 Timolol (0.1%, 0.25%, 0.5%)
Combigan® 47 2.7 Timolol (0.5%), brimonidine (0.2%)
Arutimol®/-uno 41 2.4 Timolol (0.25%, 0.5%)
nyogel® 31 1.8 Timolol (0.1%)
Timo-comod® 30 1.7 Timolol (0.25%, 0.5%)
Clonid-Ophtal® 28 1.6 Clonidine (0.063%, 0.125%)
Vistagan® 25 1.5 Levobunolol (0.1%, 0.25%, 0.5%)
Timohexal® 21 1.2 Timolol (0.1%, 0.25%, 0.5%)
Note: *individual patients could have received more than one category of intraocular 
pressure-lowering medication.Clinical Ophthalmology 2010:4 submit your manuscript | www.dovepress.com
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Over half of the total population achieved an IOP 
of #16 mmHg by the end of the study at three months; 
56.2% of right eyes and 54.8% of left eyes achieved an 
IOP #16 mmHg (Figure 2). In over a quarter of eyes studied 
(left and right), IOP was further reduced to #14 mmHg by 
three months (Figure 2). Physicians rated overall efficacy of 
BTFC on IOP reduction as “excellent” or “good” in 89.2% 
of the overall group.
Tolerability and safety
Few adverse events were associated with the use of BTFC 
(7.7%), and most patients (92%) reported no adverse events. 
The most commonly reported adverse events (in .1% of 
patients) were eye irritation (2.2%), ocular hyperemia (1.6%), 
and conjunctival hyperemia (1.5%). The tolerability of BTFC 
was rated as “excellent” or “good” by 92.3% of physicians and 
85.8% of patients at three months. Compliance with treatment, 
as rated by the physician, was rated as better than (35.4%) or 
the same as (57.5%) that with previous therapy. Continuation 
of BTFC therapy beyond the end of the study was 82.9%.
Discussion
In this German observational study reflecting clinical 
practice conditions, a large group of patients with primary 
open-angle glaucoma and ocular hypertension achieved 
further IOP reductions after switching therapy to BTFC. The 
change in IOP over the three-month observation period was 
highly significant (P , 0.0001 by t-test). Most patients were 
switched to BTFC because of insufficient IOP lowering with 
their previous therapy. BTFC treatment was also associated 
with a low incidence of conjunctival hyperemia (1.5%), 
good tolerability, and improved compliance compared with 
prior treatment.
In a double-masked, randomized study of 445 patients 
with glaucoma or ocular hypertension, a significantly lower 
incidence of conjunctival hyperemia was observed with 
the fixed combination of BTFC (8.5%) versus the nonfixed 
combination (12.5%) or single agent bimatoprost (18.9%).14 
A further study in 53 patients with glaucoma showed an 
improvement in hyperemia in 69% of patients switching from 
prior combination treatment to BTFC.16
Prior to switching to BTFC, patients in this study were 
taking a variety of therapies, including monotherapies and 
combined treatments, with the majority receiving timolol 
(57.5%) or latanoprost (23.8%). There are few published 
data regarding switching from a prior therapy to BTFC, 
but some smaller studies have shown significant reduc-
tions in IOP after switching to BTFC in patients whose IOP 
was inadequately controlled on previous therapies.16–18 An 
observational study of 606 patients switched to BTFC from 
monotherapy (66.8%), nonfixed combinations (17.2%), 
and other fixed combinations (16.0%) showed additional 
IOP reductions versus baseline. Furthermore, patients who 
had previously received β-blocker or prostaglandin analog 
treatment achieved an additional 25.8% or 22.6% decrease 
in IOP from baseline, respectively, after switching to BTFC 
treatment.18 After three months of BTFC treatment, 85% of 
all eyes achieved an IOP of #18 mmHg, which is similar to 
the findings in the current study.
Another study of 102 patients who switched to BTFC 
following inadequate treatment with monotherapy, or combi-
nation or fixed combination treatments also showed a decrease 
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in mean IOP from baseline after two months.17 The reasons for 
the greater IOP lowering achieved when patients switch from 
previous therapy to BTFC may relate to improved compliance 
resulting from once-daily administration.11
This was an open-label observational study including 
many centers. Such a study has inherent limitations, which 
must be acknowledged. For instance, the noninterventional 
nature of the study means that there could be no washout 
period between the earlier prior medications and the switch 
to BTFC. The design is also essentially uncontrolled, 
making interpretation more difficult. However, the study 
captures important information regarding the use of fixed 
combinations in everyday life, and the results confirm that 
BTFC offers good efficacy and tolerability to patients with 
primary open-angle glaucoma or ocular hypertension with 
insufficient IOP control on previous therapy. These findings 
should be considered alongside results from well controlled, 
randomized clinical trials to guide the use of IOP-lowering 
therapy in clinical practice.
Conclusion
In this observational study, three months of BTFC treatment 
resulted in significant IOP reductions in a large group of 
patients in a German clinical setting, where most patients 
were previously insufficiently controlled on other hypotensive 
agents. BTFC was well tolerated and associated with a low 
rate of adverse events, a high level of both patient and physi-
cian reported satisfaction, and good adherence to treatment.
Disclosure
Allergan Ltd funded this study and provided the services of 
Darwin Healthcare Communications for editorial support.
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